Clinical Trial

Steroid Injection in Idiopathic Granulomatous Mastitis

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 22, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
Granulomatous mastitis (GM) is a non-infectious inflammatory breast condition typically affecting young women, often following breastfeeding. Management of GM often begins with anti-inflammatory medications and antibiotics. Steroids, particularly intralesional corticosteroids, are considered the first-line treatment for GM due to their rapid anti-inflammatory and immunosuppressive effects. Steroids help control symptoms such as painful lumps, swelling, and redness. Steroids' effectiveness in providing symptom relief minimizes the need for more invasive treatments such as surgery.
Trial Details
NCT Number NCT06985537
Lead Sponsor Assiut University
Conditions Idiopathic Granulomatous Mastitis
Enrollment 40 participants
Start Date 2025-06
Primary Completion 2026-01 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2025-05-22